Lusaris is a biotechnology company advancing next-generation serotonergic neuroplastogen therapeutics to treat severe neuropsychiatric and neurological disorders. Our lead program, LSR-1019, is a proprietary sublingual formulation of 5-MeO-DMT, a rapidly acting and rapidly clearing serotonergic psychedelic in development for treatment-resistant depression and other neuropsychiatric conditions. In addition to LSR-1019, our pipe...
Lusaris is a biotechnology company advancing next-generation serotonergic neuroplastogen therapeutics to treat severe neuropsychiatric and neurological disorders. Our lead program, LSR-1019, is a proprietary sublingual formulation of 5-MeO-DMT, a rapidly acting and rapidly clearing serotonergic psychedelic in development for treatment-resistant depression and other neuropsychiatric conditions. In addition to LSR-1019, our pipeline includes novel neuroplastogens for a wide range of neuropsychiatric and neurological conditions including migraine and cluster headache.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.